These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 8414522

  • 21. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M.
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [Abstract] [Full Text] [Related]

  • 22. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH, Shore SK, Newkirk TA, Reddy RM, Reddy EP.
    Blood; 1995 Apr 15; 85(8):2162-70. PubMed ID: 7718886
    [Abstract] [Full Text] [Related]

  • 23. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A, Banerjee D, Chandra S, Banerjee S.
    J Gene Med; 2006 Oct 15; 8(10):1251-61. PubMed ID: 16952195
    [Abstract] [Full Text] [Related]

  • 24. Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
    Wu HK, Minden MD.
    Biochem Biophys Res Commun; 1997 Apr 28; 233(3):806-12. PubMed ID: 9168938
    [Abstract] [Full Text] [Related]

  • 25. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S, Chai YB, Liu F, Zhang XY, Jia W, Xie X, Yu WQ, Shang ZC, Jin BQ, Sun BZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 19; 85(3):198-202. PubMed ID: 15854468
    [Abstract] [Full Text] [Related]

  • 26. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 27. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA.
    Cai DW, Mukhopadhyay T, Roth JA.
    Cancer Gene Ther; 1995 Sep 12; 2(3):199-205. PubMed ID: 8528963
    [Abstract] [Full Text] [Related]

  • 28. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy.
    Scherr M, Battmer K, Schultheis B, Ganser A, Eder M.
    Gene Ther; 2005 Jan 12; 12(1):12-21. PubMed ID: 15602589
    [Abstract] [Full Text] [Related]

  • 29. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH, Shore SK, Reddy EP.
    Leuk Lymphoma; 1996 Aug 12; 22(5-6):365-73. PubMed ID: 8882949
    [Abstract] [Full Text] [Related]

  • 30. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
    Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ.
    Blood; 1993 Jul 15; 82(2):600-5. PubMed ID: 8329715
    [Abstract] [Full Text] [Related]

  • 31. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G, Cignetti A, Panuzzo C, Kuka M, Vitaggio K, Brancaccio M, Perrone G, Rinaldi M, Prato G, Fava M, Geuna M, Pautasso M, Casnici C, Signori E, Tonon G, Tarone G, Marelli O, Fazio VM, Saglio G.
    Cancer Res; 2007 Jun 01; 67(11):5300-7. PubMed ID: 17545610
    [Abstract] [Full Text] [Related]

  • 32. Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs.
    Lange W, Daskalakis M, Finke J, Dölken G.
    FEBS Lett; 1994 Jan 31; 338(2):175-8. PubMed ID: 8307177
    [Abstract] [Full Text] [Related]

  • 33. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J, Beltrán de Heredia JM, Odero MD, Prósper F, Calasanz MJ.
    Cancer Genet Cytogenet; 2005 Jul 01; 160(1):22-6. PubMed ID: 15949566
    [Abstract] [Full Text] [Related]

  • 34. [Study on the targeting effects of M1-GS RNA on K562 cells].
    Chen BB, Lin GW, Lu HZ, Fan HH, Gao L.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep 01; 25(9):552-5. PubMed ID: 15569537
    [Abstract] [Full Text] [Related]

  • 35. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW, Ren R.
    Oncogene; 2000 Dec 14; 19(54):6286-96. PubMed ID: 11175343
    [Abstract] [Full Text] [Related]

  • 36. Oncogene inactivation in a mouse model.
    Tanabe T, Kuwabara T, Warashina M, Tani K, Taira K, Asano S.
    Nature; 2000 Aug 03; 406(6795):473-4. PubMed ID: 10952298
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
    Warashina M, Kuwabara T, Nakamatsu Y, Taira K.
    Chem Biol; 1999 Apr 03; 6(4):237-50. PubMed ID: 10099134
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.